AbbVie jumps into $405M CF deal with Galapagos

AbbVie ($ABBV) is on a roll. One day after the U.S.-based drugmaker announced an $840 million deal with Ablynx to develop a new anti-inflammatory drug, AbbVie said it has inked a $405 million deal with Belgium's Galapagos to target genetic mutations in patients with cystic fibrosis. Report